Zobair M. Younossi – 22 December 2017 – Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.

Carlo D. L. Ceresa, David Nasralla, Constantin C. Coussios, Peter J. Friend – 22 December 2017 – In recent years, there has been growing interest in normothermic machine perfusion (NMP) as a preservation method in liver transplantation. In most countries, because of a donor organ shortage, an unacceptable number of patients die while awaiting transplantation. In an attempt to increase the number of donor organs available, transplant teams are implanting a greater number of high‐risk livers, including those from donation after circulatory death, older donors, and donors with steatosis.

Zobair M. Younossi – 22 December 2017 – Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.

Elliot B. Tapper, Anna S.‐F. Lok, Grace L. Su – 21 December 2017

Hamish Innes, Andrew McAuley, David Goldberg, Sharon J. Hutchinson – 21 December 2017

Matthew Jacob, Rehan Saif, Jayanth Reddy, Noushif Medappil, Sonal Asthana, Rajiv Lochan – 21 December 2017

Giuseppe Mazza, Walid Al‐Akkad, Krista Rombouts, Massimo Pinzani – 21 December 2017 – The term “liver tissue engineering” summarizes one of the ultimate goals of modern biotechnology: the possibility of reproducing in total or in part the functions of the liver in order to treat acute or chronic liver disorders and, ultimately, create a fully functional organ to be transplanted or used as an extracorporeal device.

Stefan Stender, Eriks Smagris, Bo K. Lauridsen, Klaus F. Kofoed, Børge G. Nordestgaard, Anne Tybjærg‐Hansen, Len A. Pennacchio, Diane E. Dickel, Jonathan C. Cohen, Helen H. Hobbs – 21 December 2017 – Genetic variation at rs4240624 on chromosome 8 is associated with an attenuated signal on hepatic computerized tomography, which has been attributed to changes in hepatic fat. The closest coding gene to rs4240624, PPP1R3B, encodes a protein that promotes hepatic glycogen synthesis.

Elisabetta Morello, Salvatore Sutti, Beatrice Foglia, Erica Novo, Stefania Cannito, Claudia Bocca, Martina Rajsky, Stefania Bruzzì, Maria Lorena Abate, Chiara Rosso, Cristina Bozzola, Ezio David, Elisabetta Bugianesi, Emanuele Albano, Maurizio Parola – 21 December 2017 – Mechanisms underlying progression of nonalcoholic fatty liver disease (NAFLD) are still incompletely characterized. Hypoxia and hypoxia‐inducible factors (HIFs) have been implicated in the pathogenesis of chronic liver diseases, but the actual role of HIF‐2α in the evolution of NAFLD has never been investigated in detail.

Juhoon So, Mehwish Khaliq, Kimberley Evason, Nikolay Ninov, Benjamin L. Martin, Didier Y.R. Stainier, Donghun Shin – 21 December 2017 – Malformations of the intrahepatic biliary structure cause cholestasis, a liver pathology that corresponds to poor bile flow, which leads to inflammation, fibrosis, and cirrhosis. Although the specification of biliary epithelial cells (BECs) that line the bile ducts is fairly well understood, the molecular mechanisms underlying intrahepatic biliary morphogenesis remain largely unknown.